Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-12-12
2006-12-12
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S402000, C530S403000
Reexamination Certificate
active
07148324
ABSTRACT:
Compositions and methods for eliciting an in vivo cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC).
REFERENCES:
patent: 4772547 (1988-09-01), Heimer et al.
patent: 5135736 (1992-08-01), Anderson et al.
patent: 5831016 (1998-11-01), Wang et al.
patent: 2002/0077288 (2002-06-01), Frangione et al.
patent: 497 997 (1992-08-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 96/10038 (1996-04-01), None
patent: WO 96/12009 (1996-04-01), None
Kim et al. J. Immunol. 159: 1666-1668, 1997.
Guermonprez et al. J. Immunol. 162(4): 1910-1916, 1999, ABSTRACT.
Osicka et al. Infect. Immun. 68/1: 247-256, 2000.
Bennett, S.R.M., et al., “Help for cytotoxic-T-cell responses is mediated by CD40 signalling”Nature393:478-480 (1998).
Brossart, P., et al., “Virus-Mediated Delivery of Antigenic Epitopes into Dendritic Cells as a Means to Induce CTL”J. Immunol. 158:3270-3276 (1997).
Czerniecki, B.J., et al., “Calcium Ionophore-Treated Peripheral Blood Monocytes and Dendritic Cells Rapidly Display Characteristics of Activated Dendritic Cells”J. Immunol. 159:3823-3837 (1997).
Greenberg, P.D., “Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells”Advances in Immunol. 49:281-355 (1991).
Jameson, S.C., et al., “Clone-specific T Cell Receptor Antagonists of Major Histocompatibility Complex Class I-restricted Cytotoxic T Cells”J. Exp. Med. 177:1541-1550 (1993).
Newell, M.K., et al., “Litigation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes”Proc Natl Acad Sci USA90:10459-10463 (1993).
Ridge, J.P., et al., “A conditioned dendritic cell can be a temporal bridge between a CD4+T-helper and a T-killer cell”Nature393:474-478 (1998).
Truman, J.-P., et al., “HLA class II signaling mediates cellular activation and programmed cell death”Exp Hematol24:1409-1415 (1996).
Vidovic, D., et al., “Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments”Eur J Immunol25:3349-3355 (1995).
Buschle, M., et al., “Transloading of tumor antigen-derived peptides into antigen-presenting cells”Proc. Natl. Acad. Sci. USA 94:3256-3261 (1997).
Layton, G.T., et al., “Induction of HIV-Specific Cytotoxic T Lymphocytes In Vivo With Hybrid HIV-1 V3:Ty-Virus-Like Particles”Journal of Immunology 151(2) :1097-1107 (1993).
Hakim Itzhak
Laus Reiner
Vidovic Damir
Chan Christina
Dendreon Corporation
DiBrino Marianne
Freschi Gina C
Perkins Coie LLP
LandOfFree
Compositions and methods for enhancement of major... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhancement of major..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhancement of major... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3659879